RESUMO
BACKGROUND: Androgen deprivation therapy (ADT) is the mainstay treatment for advanced prostate cancer. But ADTs with orchiectomy and gonadotropin-releasing hormone (GnRH) agonist are associated with increased risk of cardiovascular diseases, which appears less significant with GnRH antagonist. The difference of follicle-stimulating hormone (FSH) in ADT modalities is hypothesized to be responsible for ADT-associated cardiovascular diseases. METHODS: We administered orchiectomy, GnRH agonist, or GnRH antagonist in male ApoE-/- mice fed with Western diet and manipulated FSH levels by testosterone and FSH supplementation or FSH antibody to investigate the role of FSH elevation on atherosclerosis. By combining lipidomics, in vitro study, and intraluminal FSHR (FSH receptor) inhibition, we delineated the effects of FSH on endothelium and monocytes and the underlying mechanisms. RESULTS: Orchiectomy and GnRH agonist, but not GnRH antagonist, induced long- or short-term FSH elevation and significantly accelerated atherogenesis. In orchiectomized and testosterone-supplemented mice, FSH exposure increased atherosclerosis. In GnRH agonist-treated mice, blocking of short FSH surge by anti-FSHß antibody greatly alleviated endothelial inflammation and delayed atherogenesis. In GnRH antagonist-treated mice, FSH supplementation aggravated atherogenesis. Mechanistically, FSH, synergizing with TNF-α (tumor necrosis factor alpha), exacerbated endothelial inflammation by elevating VCAM-1 (vascular cell adhesion protein 1) expression through the cAMP/PKA (protein kinase A)/CREB (cAMP response element-binding protein)/c-Jun and PI3K (phosphatidylinositol 3 kinase)/AKT (protein kinase B)/GSK-3ß (glycogen synthase kinase 3 beta)/GATA-6 (GATA-binding protein 6) pathways. In monocytes, FSH upregulated CD29 (cluster of differentiation 29) expression via the PI3K/AKT/GSK-3ß/SP1 (specificity protein 1) pathway and promoted monocyte-endothelial adhesion both in vitro and in vivo. Importantly, FSHR knockdown by shRNA in endothelium of carotid arteries markedly reduced GnRH agonist-induced endothelial inflammation and atherosclerosis in mice. CONCLUSIONS: FSH is responsible for ADT-associated atherosclerosis by exaggerating endothelial inflammation and promoting monocyte-endothelial adhesion.
Assuntos
Aterosclerose , Doenças Cardiovasculares , Neoplasias da Próstata , Animais , Masculino , Camundongos , Antagonistas de Androgênios/efeitos adversos , Androgênios/deficiência , Aterosclerose/patologia , Endotélio/metabolismo , Hormônio Foliculoestimulante/genética , Hormônio Foliculoestimulante/metabolismo , Glicogênio Sintase Quinase 3 beta , Hormônio Liberador de Gonadotropina/farmacologia , Hormônio Liberador de Gonadotropina/fisiologia , Inflamação/etiologia , Monócitos/metabolismo , Fosfatidilinositol 3-Quinases , Proteínas Proto-Oncogênicas c-akt , TestosteronaRESUMO
Mechanotransduction in endothelial cells is critical to maintain vascular homeostasis and can contribute to disease development, yet the molecules responsible for sensing flow remain largely unknown. Here, we demonstrate that the discoidin domain receptor 1 (DDR1) tyrosine kinase is a direct mechanosensor and is essential for connecting the force imposed by shear to the endothelial responses. We identify the flow-induced activation of endothelial DDR1 to be atherogenic. Shear force likely causes conformational changes of DDR1 ectodomain by unfolding its DS-like domain to expose the buried cysteine-287, whose exposure facilitates force-induced receptor oligomerization and phase separation. Upon shearing, DDR1 forms liquid-like biomolecular condensates and co-condenses with YWHAE, leading to nuclear translocation of YAP. Our findings establish a previously uncharacterized role of DDR1 in directly sensing flow, propose a conceptual framework for understanding upstream regulation of the YAP signaling, and offer a mechanism by which endothelial activation of DDR1 promotes atherosclerosis.
Assuntos
Receptor com Domínio Discoidina 1 , Receptores Proteína Tirosina Quinases , Receptor com Domínio Discoidina 1/metabolismo , Receptores Proteína Tirosina Quinases/metabolismo , Mecanotransdução Celular , Células Endoteliais/metabolismo , Transdução de SinaisRESUMO
The MoS2/ACx catalyst for hydrogenation of naphthalene to tetralin was prepared with untreated and modified activated carbon (ACx) as support and characterized by X-ray powder diffraction, Brunauer-Emmett-Teller, scanning electron microscopy, temperature-programmed desorption of ammonia, X-ray photoelectron spectroscopy, and scaning transmission electron microscopy. The results show that the modification of activated carbon by HNO3 changes the physical and chemical properties of activated carbon (AC), which mainly increases the micropore surface area of AC from 1091 to 1209 m2/g, increases the micropore volume of AC from 0.444 to 0.487 cm3/g, increases the oxygen-containing functional groups of AC from 5.46 to 7.52, and increases the acidity of catalysts from 365.7 to 559.2 mmol/g. The modified catalyst showed good catalytic performance, and the appropriate HNO3 concentration is very important for the modified of activated carbon. Among all the catalysts used in this study, the MoS2/AC3 catalyst could achieve the highest yield of tetralin. It can be attributed to the moderate acidity of the catalyst, reducing the cracking of hydrogenation products. Also, the proper hydrogenation activity of MoS2 and the appropriate increase of oxygen-containing functional groups on the surface of modified activated carbon are beneficial to the dispersion of active components on the support, increasing the yield of tetralin. The catalytic performance of MoS2/AC3 is better than that of MoS2/Al2O3 catalyst, and the two catalysts show different hydrogenation paths of naphthalene.